What Stemgent does

Stemgent is a sub-brand of REPROCELL (Tokyo Stock Exchange: 4978.T) positioned as "The Stem Cell Experts," providing reagents, gene editing services, and GMP-grade cell manufacturing for induced pluripotent stem cell (iPSC) research and cell therapy development. The platform is anchored on StemRNA™ footprint-free RNA reprogramming technology for generating iPSC lines, the StemEdit™ gene editing service line (including AI-designed CRISPR for hypoimmune iPSC engineering), and GMP iPSC and iMSC Master Cell Bank manufacturing spanning facilities in Japan, the United States, and Europe (via a Histocell partnership), with additional operations in the UK and India (Bioserve subsidiary).

The portfolio spans research-grade reagents and ready-to-use iPSC lines through clinical-grade services including custom reprogramming, donor recruitment, gene editing, GMP cell manufacturing, and iPSC-derived exosome production. Customer segments include cell therapy developers, academic stem cell researchers, diagnostic developers, preclinical drug developers, and clinical drug developers, served through direct sales offices in the Americas, EMEA, Japan, and India, supplemented by a global distributor network and an online product catalog.

Revenue mechanics are split between distributed catalog sales of reagents, cells, and 3D culture products (including distributed partner brands such as Qkine, KOKEN, and Alvetex) and higher-value enterprise contracts for custom reprogramming, StemEdit gene editing, GMP manufacturing, and central lab/clinical trial services. Pricing is not publicly disclosed and is handled via inquiry-based quotes. Stemgent-specific revenue is not separately reported and is consolidated within REPROCELL's financials.

Name

Stemgent

Legal name

Stemgent

Website

https://stemgent.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Stemgent is the stem cell sub-brand of REPROCELL, providing iPSC reprogramming reagents (StemRNA), gene editing services (StemEdit), and GMP-grade iPSC manufacturing for cell therapy developers, academic researchers, and pharma/biotech customers globally.

Ownership category

akta.pro rank

Product category

Stem cell reagents and iPSC services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Stem cell reagents
• IPSC reprogramming kits
• Gene editing services
• GMP cell manufacturing
• Regenerative medicine tools

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Distribution channels5 records

Marketing channels5 records

Core offering

Stemgent provides stem cell research reagents, custom induced pluripotent stem cell (iPSC) reprogramming services, gene editing services (StemEdit), and GMP-grade iPSC manufacturing for researchers and cell therapy developers. Offerings span from catalog research products (RNA reprogramming kits, cytokines, growth factors) to clinical-grade Master Cell Bank production and iPSC-derived exosome manufacturing for therapeutic applications.

Product overview

Stemgent is a sub-brand of REPROCELL positioned as "The Stem Cell Experts" within REPROCELL's portfolio of four brands (Bioserve, Stemgent, Alvetex, and Biopta). Stemgent offers an integrated platform for stem cell research and development, combining StemRNA technology (reprogramming kits and characterized iPSC lines) with StemEdit gene editing services and products. The offering spans research-use products (StemRNA 3rd Gen Reprogramming Kit, ready-to-use iPSCs) through clinical-grade services (GMP iPSC production, StemEdit Clinical Gene Editing). The portfolio provides end-to-end solutions from donor sourcing and footprint-free reprogramming to precise gene editing and GMP manufacturing, enabling researchers and cell therapy developers to generate reliable, publication-ready data and scalable therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• StemRNA 3rd Gen Reprogramming Kit RNA-based reprogramming kit that enables generation of induced pluripotent stem cells (iPSCs) from somatic cells using StemRNA footprint-free technology, intended for stem cell researchers and cell therapy developers.
• StemRNA Human iPSCs Ready-to-use research-grade induced pluripotent stem cell lines produced via StemRNA RNA-based reprogramming, providing characterized and quality-controlled pluripotent stem cells for research applications.
• StemEdit Gene Editing Services Custom gene editing services and products for stem cells, offering knockout, knock-in, and hypoimmune engineering capabilities for researchers and clinical-stage cell therapy developers.
• StemEdit Hypoimmune Cell Lines Gene-edited iPSC lines featuring hypoimmune modifications such as B2M knockout, designed to reduce immune rejection for off-the-shelf cell therapy applications.
• GMP iPSC & iMSC MCB Manufacturing Clinical-grade GMP-compliant manufacturing service producing induced pluripotent stem cells (iPSCs) and induced mesenchymal stem cells (iMSCs) with Master Cell Bank (MCB) capabilities, for cell therapy developers requiring regulatory-aligned manufacturing.
• iPSC-Derived Exosome Production Service Custom production of exosomes derived from induced pluripotent stem cells (iPSCs) for therapeutic development and research applications.
• Stem Cell Reagent Product Catalog A comprehensive catalog offering of stem cell research reagents — including RNA reprogramming kits, small molecules, growth factors, cytokines, antibodies, staining kits, culture media, cell substrates, cryopreservation media, dissociation solutions, and transfection reagents — sold to academic and industrial stem cell researchers.
• Stem Cell Product Catalog Catalog offering of cell products supporting stem cell research and cell-based therapies, including iPSC-derived exosomes and related reagents.

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• HistocellcoreStrategic or Co-development PartnerHistocell serves as REPROCELL's GMP cell manufacturing partner for Europe, providing GMP-grade iPSC and MSC (mesenchymal stem cell) MCB (Master Cell Bank) manufacturing capabilities for the European market.
• Bioserve IndiacoreStrategic or Co-development PartnerBioserve Biotechnologies (India) Private Ltd. operates as REPROCELL's Indian subsidiary, providing biospecimen services and supporting genomic services across the Indian market.
• Bioserve Partner NetworkcoreStrategic or Co-development PartnerGlobal partner network for human tissue samples and biospecimen procurement, enabling access to specimens across multiple geographies for diagnostic and preclinical research.
• QkineminorChannel Partner/ Reseller/ DistributorQkine provides growth factors and cytokines that are distributed through REPROCELL's product catalog as part of the stem cell reagent offerings.
• KOKENminorChannel Partner/ Reseller/ DistributorKOKEN's Atelocollagen (AteloCell) products for 3D cell culture are distributed through REPROCELL's product catalog.
• Human Tissue Supplier NetworkcoreStrategic or Co-development PartnerNetwork of suppliers for human tissue specimens supporting preclinical drug testing and research, enabling access to fresh human tissues for drug discovery assays.

Scale indicators2 records

Recent moves3 records

Expansion highlights6 records

Direct peers

• Stemcell Technologies: Leading specialty provider of stem cell reagents, culture media, and cell isolation products for research and clinical applications. Directly competes with Stemgent's stem cell reagent portfolio.
• Lonza: Global contract development and manufacturing organization (CDMO) offering cell therapy manufacturing services including iPSC and MSC production. Directly competes with Stemgent's GMP iPSC and MCB manufacturing capabilities.
• FUJIFILM Cellular Dynamics: Major commercial provider of iPSC lines, differentiated cell types, and iPSC-derived products for research and clinical use. Directly competes with Stemgent's StemRNA iPSCs and iPSC-derived cell offerings.

Emerging players

• Century Therapeutics: Clinical-stage company developing iPSC-derived allogeneic cell therapies with gene editing for hypoimmunity. Direct modality competitor and potential customer for Stemgent's hypoimmune iPSC engineering services.
• Fate Therapeutics: Clinical-stage biopharmaceutical company developing iPSC-derived off-the-shelf cell therapies. Represents both a potential customer for Stemgent's GMP services and a competing end-product developer in the same modality space.
• Cellino Biotech: Emerging iPSC manufacturing platform combining AI-driven automation with GMP-compliant iPSC production. Competes with Stemgent on next-generation iPSC manufacturing approaches.
• Pluristyx: iPSC technology platform offering iPSC line banking, gene editing, and cell therapy development services. Competes with Stemgent's stem cell services and iPSC banking offerings.

Broad incumbents

• Thermo Fisher Scientific: Broad life science consumables and services company offering stem cell reagents, culture media, and cell therapy development services. Competes across Stemgent's reagent catalog and certain service offerings.
• Bio-Techne: Major life science reagents company providing growth factors, cytokines, antibodies, and stem cell research products. Competes with Stemgent's Stemfactor and reagent offerings.
• Corning Life Sciences: Major supplier of cell culture products including 3D cell culture systems and culture media. Overlaps with REPROCELL/Stemgent's Alvetex 3D cell culture and media products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Stemgent
• Facebookfacebook.com/stemgent
• LinkedInlinkedin.com/company/stemgent

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stemgent